ReviewInternational journal of trichology
Cumulative Life Course Impairment of Alopecia Areata.
Review in International journal of trichology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.The Journal of dermatology · 2026Trial
- Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3.International journal of dermatology · 2026Trial
- Illness Perception, Emotional Distress, and Obsessive-Compulsive Symptomatology in Patients with Alopecia Areata: A Mediation Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges - A Narrative Review.Journal of inflammation research · 2026Review
- Impact of Alopecia Areata on Major Life-changing Decisions: Prevalence and Associated Factors.Acta dermato-venereologica · 2025Article
- Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians.Skin appendage disorders · 2025Review
- Sexual Dysfunction in Alopecia Areata: A Systematic Review.Journal of clinical medicine · 2025Review
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment.The Journal of dermatology · 2025Article
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis.Dermatology and therapy · 2024Article
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment.The Journal of dermatology · 2024Article
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey.Clinical, cosmetic and investigational dermatology · 2024Article
- Overview of alopecia areata for managed care and payer stakeholders in the United States.Journal of managed care & specialty pharmacy · 2023Article
- Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective.Journal of managed care & specialty pharmacy · 2023Article
- Out-of-Pocket Costs in Alopecia Areata: A Cross-Sectional Study in German-speaking Countries.Acta dermato-venereologica · 2023Article
- Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.Advances in therapy · 2021Article
- Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA), an unpredictable, nonscarring hair loss, is commonly perceived as a cosmetic, rather than medical, concern. However, substantial evidence exists describing the negative impact on quality of life, as the disease affects patients personally, socially, financially, and physically. Over time, the cumulative disability may perpetuate poor confidence, social disconnection, negative coping strategies, and failure to achieve a full life potential. Here, we describe the cumulative life course impairment (CLCI) of AA by examining the complex interaction of (1) stigmatization, (2) physical and psychiatric comorbidities, and (3) coping strategies. The model aggregates existing cross-sectional data, which have previously captured disease burden only as snapshots in time. Thus, by examining cumulative effects, the CLCI model serves as a proxy for longitudinal data to better describe life course epidemiology of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.